A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
NCT04890509
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
115
Enrollment
INDUSTRY
Sponsor class
Conditions
COVID-19
Interventions
DRUG:
Bemcentinib
OTHER:
SoC
Sponsor
BerGenBio ASA